OGT launches SureSeq Myeloid MRD Plus NGS panel
Nov. 11, 2025—OGT launched the SureSeq Myeloid MRD Plus NGS panel, to detect ultra-low frequency variants in key measurable residual disease–associated biomarkers in acute myeloid leukemia.
Webinars and Sponsored Roundtables — Register Now
Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.
Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Cente, and Colin Murphy, CEO of mTuitive.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, June 9, 2026, 1:00–2:00 PM ET
In this webinar, we will examine how immune recognition after allogeneic HCT can influence leukemia relapse and disease progression. The session will highlight the clinical relevance of HLA loss of heterozygosity (LOH), approaches used for its detection, and how LOH findings may support transplant strategies, including considerations for donor selection in subsequent transplantation.
Webinar presenter Alberto Cardoso Martins Lima, PhD, Clinical consulting scientist in histocompatibility,
specializing in allogeneic hematopoietic cell transplantation (HCT) at IGEN/AFIP São Paulo and CHC/UFPR in Curitiba, Brazil
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, June 24, 2026, 12:00–1:00 PM ET
Hear an expert discuss the expanded clinical utility of HER2 IHC scoring in metastatic breast cancer and its impact on your practice
Webinar presenter Michelle Shiller, DO, AP, CP, MGP, FACP, Baylor University Medical Center.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Subspecialties
Interactive Product Guides
Industry News
Randox Toxicology launches a nitazenes array
Nov. 7, 2025—Randox Toxicology has launched its Nitazenes Array, an immunoassay designed to detect a broad spectrum of nitazene analogues from a single sample.
Qiagen to acquire Parse Biosciences for $225 million
Nov. 6, 2025—Qiagen has entered into a definitive agreement to fully acquire Parse Biosciences, a provider of scalable, instrument-free solutions for single-cell research.
Proscia’s Access25 now available on demand
Nov. 5, 2025—Access25, a virtual event that featured live demos of Proscia Aperture, Proscia’s latest product offering that surfaces patient insights at the moment of diagnosis, is now available on demand by registering at Proscia.com.
FDA clears QuidelOrtho Vitros hs troponin I assay
Nov. 4, 2025—The FDA has granted QuidelOrtho Corp. 510(k) clearance for the Vitros hs Troponin I Reagent Pack.
BD enteric bacterial panels get clearance, CE-IVDR certification
Nov. 3, 2025—BD has received FDA 510(k) clearance and CE marking for its Enteric Bacterial Panel and Enteric Bacterial Panel Plus for the BD Cor system.
Bio-Rad launches enhanced Liquichek opiate control
Oct. 17, 2025—Bio-Rad Laboratories has launched an enhanced version of its Liquichek opiate control.
FDA clears Roche’s Elecsys pTau181 blood test
Oct. 16, 2025—The FDA has cleared Roche’s Elecsys pTau181 test, a blood-based biomarker test indicated as an aid in the initial assessment for Alzheimer’s disease and other causes of cognitive decline in the primary care setting.
HemoSonics gets expanded clearance for Quantra system
Oct. 15, 2025—HemoSonics has received FDA 510(k) cleared for expanded use of its Quantra hemostasis system with QStat cartridges in peripartum obstetric procedures.
VoiceOver PRO now integrates with multiple DP systems
Oct. 13, 2025—Voicebrook’s VoiceOver PRO platform now connects with multiple digital pathology systems, including those from PathAI, PathPresenter, and Gestalt Diagnostics.